Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.40 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29071984 | 0.89 | AAK1 (0.47) | CYP17A1KCNQ4KCNQ5RXFP1AAK1 | |
| SCHEMBL29393326 | 0.89 | AAK1 (0.47) | CYP17A1KCNQ4KCNQ5RXFP1AAK1 | |
| SCHEMBL3401610 | 0.87 | CYP17A1 (0.40) | CYP17A1KCNQ4KCNQ5RXFP1AAK1 | |
| SCHEMBL14725520 | 0.82 | CYP17A1 (0.48) | CYP17A1KCNQ4KCNQ5RXFP1AAK1 | |
| SCHEMBL19501761 | 0.82 | LMNA (0.42) | CYP17A1KCNQ4KCNQ5RXFP1AAK1 | |
| SCHEMBL29675308 | 0.80 | KDM4A (0.44) | LMNA | |
| SCHEMBL22482387 | 0.80 | KDM4A (0.44) | LMNA | |
| SCHEMBL3402389 | 0.80 | CA12 (0.38) | CYP17A1KCNQ4KCNQ5RXFP1AAK1 | |
| SCHEMBL2212401 | 0.80 | CETP (0.42) | LMNAPOLBDPP4DPP8DPP9 | |
| SCHEMBL22482353 | 0.80 | CYP17A1 (0.43) | CYP17A1KCNQ4KCNQ5RXFP1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250157-B1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LTD (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-2250157-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Panacea Biotec Limited (IN) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009093269-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DPP4, DPP3, DPP8 | CYP17A1 1100/4885KCNQ4 1813/4885KCNQ5 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.